Updated Jul 16, 2026
Powl Brian T. has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $346K.
Brian T. Powl serves as the Chief Commercial Officer at Kura Oncology, Inc., a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment. He has been involved in the company's operations as indicated by his SEC filings.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-22 | KURA | Kura Oncology, Inc. | S — Open-market sale | 10.0K | $11.00 | $110K |
| 2026-05-20 | KURA | Kura Oncology, Inc. | S — Open-market sale | 339 | $9.21 | $3K |
| 2026-01-28 | KURA | Kura Oncology, Inc. | S — Open-market sale | 1.6K | $8.46 | $13K |
| 2026-01-28 | KURA | Kura Oncology, Inc. | S — Open-market sale | 4.8K | $8.46 | $41K |
| 2026-01-06 | KURA | Kura Oncology, Inc. | A — Grant or award | 50.0K | $0.00 | |
| 2025-11-15 | KURA | Kura Oncology, Inc. | S — Open-market sale | 8.9K | $11.18 | $99K |
| 2025-11-15 | KURA | Kura Oncology, Inc. | A — Grant or award | 48.9K | $0.00 | |
| 2025-09-27 | KURA | Kura Oncology, Inc. | S — Open-market sale | 8.9K | $8.94 | $80K |
| 2025-09-27 | KURA | Kura Oncology, Inc. | A — Grant or award | 48.9K | $0.00 |
Brian T. Powl serves as the Chief Commercial Officer at Kura Oncology, Inc., a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment. He has been involved in the company's operations as indicated by his SEC filings.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 6 open-market sales ($346K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Powl Brian T. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.